Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026)

摘要: On November 29, 2018, experts in the field of infectious diseases, pathogen reduction technologies (PRTs) and other participants from blood centers, academia, industry gathered at Food Drug Administration (FDA) White Oak Campus Silver Spring, Maryland, for a 2‐day public workshop entitled “Pathogen Reduction Technologies Blood Safety.” The opened with welcome remarks Dr. Nicole Verdun, Director, Office Research Review (OBRR), Center Biologics Evaluation (CBER), FDA, followed by introductory Peter Marks, CBER, FDA. first day focused on blood‐borne agents their impact safety, experiences American Red Cross, establishments implementing FDA‐approved inactivation (PI) technology plasma platelets (PLTs) United States novel PRTs under consideration whole (WB) red cells (RBCs). second Chintamani Atreya, Associate Director Research, OBRR, focus was emerging innovations relevant to potential alternatives PRTs. concluded insights future research development this area product safety agents. A brief introduction each session moderator summary speaker presentation as submitted are reported here.